newsfilter
← Earnings
Earnings Releases·

Precipio — Q3-2026 Earnings Summary

  • Total revenue rose 8% year-over-year to $7.3 million, driven by a 40% increase in product revenue to $1.0 million and a 5% rise in pathology revenue to $6.3 million.
  • Adjusted EBITDA remained flat at $0.4 million, while GAAP Net Income improved to $0.0 million from a $0.1 million loss in the prior year period.
  • Cash reserves strengthened significantly, with total cash increasing by $0.5 million to exceed $3.5 million, up from $2.3 million in Q3-2025.
  • Management affirmed a strategy to accelerate commercialization of its existing product portfolio and pursue longer-term growth opportunities, citing a strong operational foundation.
Company
PRECIPIO INC
Sector
Healthcare
Industry
Diagnostics & Research